Literature DB >> 12908558

Causation and prevention of solely estrogen-induced oncogenesis: similarities to human ductal breast cancer.

Jonathan J Li1, Sara Antonia Li.   

Abstract

Estrogens are intimately involved in the causation of some of the most prevalent cancers afflicting women, particularly, breast, endometrial, cervico-vaginal, and possibly ovarian. Therefore, it has become particularly pertinent to elucidate the molecular changes and mechanisms whereby estrogens elicit their oncogenic actions so that better prevention strategies can be developed. The estrogen-induced Syrian hamster tumors of the kidney have emerged as one of the most intensively studied in-vivo models in solely estrogen-induced oncogenesis. An advantage of this model is that the tumors occur in the absence of any intervening morphologic changes, but rather they are the result of the continuous progression of a subset of interstitial stem cells in the kidney leading to tumor formation. Evidence is presented that the origin of these tumors is derived from ectopic "uterine" stem cells, which are responsive to estrogenic hormones. The other animal tumor model studied is the highly sensitive estrogen-induced mammary tumors of female ACI rats. Their steroid receptor and other gene alterations have been delineated. Importantly, a crucial early event in this solely estrogen-induced oncogenic process, common to both animal tumor models, is the overexpression and amplification of c-myc and its protein product. Chromosomal instability, in both early and large well-established frank tumors, is another important characteristic found during early E-induced oncogenesis. These features have been shown to be characteristic of human ductal carcinomas in-situ and in primary invasive ductal breast carcinomas. The molecular alterations seen are considered crucial in eliciting estrogen-induced oncogenesis and have established for the first time a direct causal link between estrogen and the induction of chromosomal instability and aneuploidy in these estrogen-associated neoplasms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908558     DOI: 10.1007/978-1-4615-0081-0_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer.

Authors:  Jie Qing Chen; Yi Bao; Jennifer Litton; Li Xiao; Hua-Zhong Zhang; Carla L Warneke; Yun Wu; Xiaoyun Shen; Sheng Wu; Ruth L Katz; Aysegul Sahin; Melissa Bondy; James L Murray; Laszlo Radvanyi
Journal:  Horm Cancer       Date:  2011-04       Impact factor: 3.869

2.  Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats.

Authors:  Athena Starlard-Davenport; Volodymyr P Tryndyak; Smitha R James; Adam R Karpf; John R Latendresse; Frederick A Beland; Igor P Pogribny
Journal:  Carcinogenesis       Date:  2009-12-14       Impact factor: 4.944

Review 3.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

4.  Regulation of bcl-2 transcription by estrogen receptor-α and c-Jun in human endometrium.

Authors:  Zhong-Lian Li; Ken Ueki; Koji Kumagai; Ryoji Araki; Yoshinori Otsuki
Journal:  Med Mol Morphol       Date:  2013-05-11       Impact factor: 2.309

5.  The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat.

Authors:  Aliccia Bollig-Fischer; Archana Thakur; Yuan Sun; Jiusheng Wu; D Joshua Liao
Journal:  Int J Biomed Sci       Date:  2012-03

6.  Oxidative stress specifically downregulates survivin to promote breast tumour formation.

Authors:  S Pervin; L Tran; R Urman; M Braga; M Parveen; S A Li; G Chaudhuri; R Singh
Journal:  Br J Cancer       Date:  2013-02-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.